GlassScriptPhysician profile
Nathan Blake John
NPI 1972036168
$2,746.96
in general payments reported to CMS, 2019-2025
31 companies · $1,126 in 2025
The $1,126 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $704 · 2024: $918 · 2025: $1,126.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,747.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,746.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $532.95 | 2023-2025 | |
| Amgen INC. | $340.18 | 2023-2025 | Prolia, Repatha, Otezla |
| Novo Nordisk INC | $221.92 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Corcept Therapeutics | $186.61 | 2023-2025 | Korlym |
| Abbott Laboratories | $167.02 | 2024 | Freestyle Libre 3 |
| Pfizer INC. | $143.96 | 2025 | |
| Lilly USA, LLC | $125.76 | 2023-2025 | Jardiance, Mounjaro, Zepbound |
| Axsome Therapeutics, INC. | $113.63 | 2024-2025 | Auvelity, Symbravo |
| Glaxosmithkline, LLC. | $100.61 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $81.51 | 2024-2025 | Airsupra |
| Eisai INC. | $67.43 | 2023-2025 | |
| Exact Sciences Corporation | $66.44 | 2024-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.84 | 2023-2024 | Jardiance, Synjardy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $64.11 | 2024-2025 | Xifaxan, Trulance |
| Organon LLC | $50.10 | 2025 | Nexplanon |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $39.37 | 2024-2025 | Xyosted |
| Jazz Pharmaceuticals INC. | $37.16 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $37.08 | 2025 | Zoryve |
| Kyowa Kirin, INC. | $35.03 | 2024 | Nourianz |
| Bayer Healthcare Pharmaceuticals INC. | $34.10 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $33.32 | 2024 | Gardasil, Gardasil 9, Capvaxive |
| Nevro Corp. | $26.03 | 2024 | Senza |
| Astellas Pharma US INC | $26.01 | 2024 | Veozah |
| Lundbeck LLC | $25.37 | 2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $22.96 | 2025 | Spravato |
| Idorsia Pharmaceuticals US INC | $19.70 | 2023 | Quviviq |
| Halozyme INC | $19.45 | 2023 | |
| Phathom Pharmaceuticals, INC. | $18.91 | 2025 | Voquezna |
| Insulet Corporation | $15.68 | 2024 | Omnipod |
| Sanofi Pasteur INC. | $14.46 | 2023 | |
| Shield Therapeutics INC | $14.26 | 2023 | Accrufer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan John listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.